AAN 2022 | The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab

The CHIMES trial (NCT04377555) is an open-label, Phase IV study assessing disease activity and biomarkers of neuronal damage in minority patients (self-identified Black or African American and Hispanic/Latino) receiving treatment with ocrelizumab. Lilyana Amezcua, MD, FAAN, Keck School of Medicine, University of Southern California, Los Angeles, CA, shares the baseline demographics and disease characteristics of Black and Hispanic patients with relapsing multiple sclerosis (RMS) enrolled in the CHIMES trial. Potential distinguishing factors identified included younger age, higher BMI, greater T2 burden, shorter duration of disease, and time to diagnosis despite similar disease activity to patients from other ocrelizumab studies. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.